PMID- 17716237
OWN - NLM
STAT- MEDLINE
DCOM- 20080225
LR  - 20081121
IS  - 1744-8042 (Electronic)
IS  - 1462-2416 (Linking)
VI  - 8
IP  - 8
DP  - 2007 Aug
TI  - Evidence-based management of nutrigenomics expectations and ELSIs.
PG  - 1051-62
AB  - Nutrigenomics is a new application context for genomics technologies that focuses 
      on the bidirectional study of genetic factors influencing host (individuals' or 
      populations') response to diet and the effects of bioactive constituents in food 
      on host genome and gene expression. Nutrigenomics is considered the next wave 
      after pharmacogenomics for individualization of health interventions. However, 
      relatively little attention has been given to the specific ethical-legal-social 
      issues (ELSIs) and sociotechnical expectations raised by nutrigenomics research. 
      Some of the ELSIs, such as ensuring privacy of genetic information and 
      implications of genetic testing for health insurance and employment, may be 
      shared across the continuum of genomic technology applications in human disease 
      genetics, pharmacogenomics and nutrigenomics. However, there are certain aspects 
      of nutrigenomics research that may result in unique or unprecedented ELSIs. For 
      example, nutrigenomics has a strong focus on public health and the 
      prevention/modification of 'predisease phenotypes' in apparently healthy 
      individuals. Thus, in contrast to previous applications of genomics technologies, 
      where the goal is to distinguish existing disease from absence of disease, the 
      aim of nutrigenomics is the discernment of nuanced differences in predisease 
      states. Moreover, there is evidence to suggest that ELSIs may be different in 
      biomarker discovery, translational research and clinical testing stages of 
      nutrigenomics. Ideally, ELSI research and nutrigenomics bioscience should 
      progress in parallel and in a commensurate manner. We suggest that qualitative 
      research methods, using a hypothesis-free approach, can be employed to gain 
      deeper insights on complex bioethics issues that do not ordinarily lend 
      themselves to formal hypothesis testing with the quantitative methods used in 
      biomedical sciences.
FAU - Ozdemir, Vural
AU  - Ozdemir V
AD  - Department of Preventive and Social Medicine, Bioethics Programs, Faculty of 
      Medicine, University of Montreal C.P. 6128, Succ. Centre-Ville, Montreal, Quebec, 
      H3C 3J7, Canada.
FAU - Godard, Beatrice
AU  - Godard B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Pharmacogenomics
JT  - Pharmacogenomics
JID - 100897350
SB  - IM
MH  - Animals
MH  - Diet/methods/trends
MH  - Evidence-Based Medicine/*ethics/methods/*trends
MH  - Genome, Human/genetics
MH  - Humans
MH  - Nutrigenomics/*ethics/methods/*trends
MH  - Nutritional Physiological Phenomena/genetics
RF  - 76
EDAT- 2007/08/25 09:00
MHDA- 2008/02/26 09:00
CRDT- 2007/08/25 09:00
PHST- 2007/08/25 09:00 [pubmed]
PHST- 2008/02/26 09:00 [medline]
PHST- 2007/08/25 09:00 [entrez]
AID - 10.2217/14622416.8.8.1051 [doi]
PST - ppublish
SO  - Pharmacogenomics. 2007 Aug;8(8):1051-62. doi: 10.2217/14622416.8.8.1051.